Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Exelixis
Related studies linked through entity extraction aliases.
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
- Status
- TERMINATED
- Phase
- PHASE2
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
- Status
- COMPLETED
- Phase
- PHASE1
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- Status
- RECRUITING
- Phase
- PHASE2
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
- Status
- COMPLETED
- Phase
- PHASE3
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE3